首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Single photon emission computed tomography-based three-dimensional conformal radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus.
【24h】

Single photon emission computed tomography-based three-dimensional conformal radiotherapy for hepatocellular carcinoma with portal vein tumor thrombus.

机译:基于单光子发射计算机断层扫描的三维保形放射治疗肝癌合并门静脉肿瘤血栓。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To evaluate the safety and efficacy of three-dimensional conformal radiotherapy (3D-CRT) using single photon emission computed tomography (SPECT) in unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT). METHODS AND MATERIALS: Patients with HCC with PVTT in the first branch and/or main trunk were selected for this study. The optimal beam directions for 3D-CRT were explored using a Tc-99m-galactosyl human serum albumin SPECT image for guidance. The SPECT image was classified as either wedge type or localized type. The clinical target volume to a total dose of 45 or 50 Gy per 18-20 fractions included the main tumor and PVTT in the wedge type and PVTT alone in the localized type. RESULTS: Twenty-six patients were enrolled: 18 with wedge type and 8 with localized type. Mean tumor size was 7.1 cm (range, 4.4-12.3 cm). Clinical target volumes of wedge type vs. localized type were 111.2 cm(3) vs. 48.4 cm(3) (p = 0.010), respectively. Mean dose to normal liver and mean dose to functional liver were 1185 cGy and 988 cGy (p = 0.001) in wedge type and 1046 cGy and 1043 cGy (p = 0.658) in localized type, respectively. Despite an incidence of Child-Pugh B and C of 57.7%, no patients experienced radiation-induced liver disease. The progression of PVTT was inhibited, with an incidence of 92.2%; survival rates at 1 and 2 years were 44% and 30%, respectively. CONCLUSION: Single photon emission computed tomography-based 3D-CRT enables irradiation of both the main tumor and PVTT with low toxicity and promising survival.
机译:目的:评估使用单光子发射计算机断层扫描(SPECT)的三维保形放射治疗(3D-CRT)在不可切除的肝细胞癌(HCC)合并门静脉肿瘤血栓(PVTT)的安全性和有效性。方法和材料:本研究选择第一分支和/或主干中患有PVTT的HCC患者。使用Tc-99m-半乳糖基人血清白蛋白SPECT图像探索3D-CRT的最佳光束方向,以进行指导。 SPECT图像分为楔型或局部型。每18-20个部分的总剂量45或50 Gy的临床目标体积包括楔形型的主要肿瘤和PVTT,局部型的仅PVTT。结果:26例患者入选:楔型18例,局部型8例。平均肿瘤大小为7.1厘米(范围:4.4-12.3厘米)。楔型与局部型的临床目标体积分别为111.2 cm(3)和48.4 cm(3)(p = 0.010)。楔形类型的正常肝平均剂量和功能性肝的平均剂量分别为1185 cGy和988 cGy(p = 0.001),局部型分别为1046 cGy和1043 cGy(p = 0.658)。尽管Child-Pugh B和C的发生率为57.7%,但没有患者经历过辐射诱发的肝病。 PVTT的进展受到抑制,发生率为92.2%; 1年和2年生存率分别为44%和30%。结论:基于单光子发射计算机断层扫描的3D-CRT能够以低毒性和有希望的存活率照射主要肿瘤和PVTT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号